SOPs for Drug Discovery

The purpose of this Standard Operating Procedure (SOP) is to define the procedures for conducting exploratory toxicology studies. These studies aim to evaluate the potential toxic effects of a drug candidate in an early stage of development. Exploratory toxicology studies provide valuable data to assess the safety profile of a compound before progressing to more comprehensive preclinical safety assessments. The data generated in these studies help identify potential risks and guide decisions regarding the drug’s development.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to outline the procedures for conducting preclinical safety pharmacology studies. These studies are essential for evaluating the potential effects of a drug candidate on vital organ systems, including the cardiovascular, respiratory, and central nervous systems, to ensure the safety of the drug prior to clinical trials. This SOP ensures that safety pharmacology studies are conducted according to regulatory guidelines and are documented comprehensively for regulatory review.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to define the procedures for integrating preclinical study data into an Investigational New Drug (IND) submission. This SOP ensures that preclinical data is appropriately analyzed, compiled, and presented in the IND application to support the safety, efficacy, and quality of the drug candidate. The goal is to comply with regulatory requirements and facilitate a smooth submission process for the clinical trial authorization.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to establish the procedure for preparing preclinical study reports. This SOP ensures that study reports are accurately and comprehensively prepared, following the data analysis and interpretation of preclinical studies. The preparation of these reports is essential to document the study findings, support regulatory submissions, and provide a clear record of the study’s execution and outcomes.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to outline the process for the ethical review and approval of preclinical studies. This SOP ensures that all preclinical studies involving animals are conducted in compliance with ethical standards, regulatory guidelines, and animal welfare laws. It provides guidance on obtaining ethical review and approval for the study protocol before commencing any animal research activities, thus safeguarding the rights of the animals used in research.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to establish the procedures for managing and archiving preclinical study data. Proper data management ensures that study data is accurate, complete, and accessible for future reference. Archiving study data in compliance with Good Laboratory Practice (GLP) standards is essential for maintaining data integrity, ensuring compliance with regulatory requirements, and supporting the reproducibility and transparency of preclinical studies.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to define the procedures for conducting preclinical studies in compliance with Good Laboratory Practice (GLP). GLP is a set of principles that ensures the quality, integrity, and reproducibility of data in non-clinical laboratory studies. This SOP outlines the requirements for study planning, execution, documentation, and reporting to ensure that preclinical studies are conducted according to GLP standards.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to establish the procedure for bioanalytical sample analysis and the subsequent reporting of results. This process is critical in ensuring that the data generated from bioanalytical testing are accurate, reliable, and suitable for pharmacokinetic studies, efficacy evaluations, and safety assessments in preclinical and clinical trials. The SOP provides detailed instructions for handling bioanalytical samples, performing the analysis, interpreting the results, and compiling the findings into comprehensive reports for further regulatory review.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to define the procedures for preparing bioanalytical methods used to quantify and analyze the concentration of drug candidates and their metabolites in biological samples during preclinical studies. Bioanalytical methods are crucial for determining pharmacokinetic profiles, assessing the bioavailability of compounds, and supporting the evaluation of drug safety and efficacy. This SOP ensures the development and validation of bioanalytical methods that are accurate, reliable, and suitable for the intended study.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to define the procedures for conducting cardiotoxicity testing in preclinical animal models. Cardiotoxicity testing is essential for assessing the potential adverse effects of drug candidates on the heart, including arrhythmias, heart failure, and other cardiovascular issues. This SOP ensures that cardiotoxicity studies are performed in a standardized and reproducible manner, providing valuable data to support the safety of drug candidates before clinical trials.
Click to read the full article.